Prostate Cancer Clinical Trials in Anaheim, CA

Prostate Cancer Clinical Trials in Anaheim, CA

View the best 10 prostate cancer medical studies in Anaheim, California. Access promising new therapies by applying to a Anaheim-based Prostate Cancer clinical trial.

Trials in Anaheim, California

Here are the top 10 medical studies for prostate cancer in Anaheim, California

Image of Tower Urology in Los Angeles, United States.

Copper Cu 64 PSMA I&T

Cancer Imaging Agent

Recruiting2 awardsPhase 3
This trial will test a new imaging technique using copper Cu 64 PSMA I&T injection in patients with newly diagnosed aggressive prostate cancer to see if it can help doctors better visualize the extent of the cancer
Image of University of Alabama at Birmingham in Birmingham, United States.

Abiraterone

Androgen Deprivation Therapy

Recruiting1 awardPhase 3
This trial is testing whether abemaciclib, when added to abiraterone plus prednisone, can help to treat prostate cancer by prolonging the time before the cancer gets worse.
Image of Clinical Trial Site in La Jolla, United States.

ARV-766

Androgen Receptor Antagonist

Recruiting1 awardPhase 1 & 2
This trial is testing a new oral drug called ARV-766, alone or with abiraterone, in men with advanced prostate cancer that has spread. The drug works by blocking proteins that help cancer cells grow. Abiraterone is a well-established drug used in the treatment of metastatic castration-resistant prostate cancer, often in combination with other therapies.
Image of Research Site in Lakewood, United States.

Capivasertib +1 More

AKT Inhibitor

Recruiting1 awardPhase 3
This trial will compare the effect of two different treatments for metastatic prostate cancer. One group will receive a combination of capivasertib and docetaxel, while the other group will receive docetaxel and a placebo. The goal is to see if adding capivasertib to docetaxel improves survival rates.
Image of Arizona Institute of Urology, PPLC in Tucson, United States.

177Lu-PSMA-I&T +1 More

Radioisotope Therapy

Recruiting2 awardsPhase 3
This trial is testing a new radioactive drug against standard hormone therapy in men with advanced prostate cancer that doesn't respond to usual treatments. The drug targets and kills cancer cells using radiation. The drug being tested, 225Ac-PSMA-617, has shown promise in inducing complete responses in patients with metastatic castrate-resistant prostate cancer who were resistant to standard therapies.
Image of St. Vincent Frontier Cancer Center-Research ( Site 0037) in Billings, United States.

Enzalutamide +2 More

Hormone Therapy

Recruiting2 awardsPhase 3
This trial is testing a new drug called opevesostat for advanced prostate cancer patients who don't respond to usual care. The drug aims to stop the cancer from growing and spreading, potentially helping patients live longer.
Image of Arizona Urology Specialists, PLLC in Tucson, United States.

Relugolix +1 More

Hormone Therapy

Recruiting2 awardsPhase 3
This trial compared the safety and heart-related risks of two hormone-lowering medications, relugolix and leuprolide acetate, in adults with prostate cancer. These drugs help manage cancer by reducing testosterone levels. The study was discontinued, but patients can continue their treatment for a certain period. Relugolix is the first oral medication of its kind and was approved by the FDA based on previous study results.
Image of VA Long Beach Healthcare System, Long Beach, CA in Long Beach, United States.

Stereotactic Ablative Radiotherapy +1 More

Radiation

Recruiting1 awardPhase 2
This trial tests a new treatment for metastatic prostate cancer, using radiotherapy, drugs and hormone treatment.
Image of Innovative Clinical Research Institute in Whittier, United States.

SOT101 +1 More

Virus Therapy

Recruiting1 awardPhase 2
This trial is testing a new drug called nanrilkefusp alfa together with an existing cancer treatment called pembrolizumab. Pembrolizumab is already approved for various cancer treatments and is often used with other therapies to improve survival rates. The goal is to see if combining these drugs can more effectively shrink tumors by boosting the immune system's ability to fight cancer.
Image of University of California at Davis in Davis, United States.

ONC-392 +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 1 & 2
This trial tests ONC-392, an antibody that helps the immune system fight cancer, in patients with advanced or spreading tumors who haven't responded to other treatments. It works by blocking a protein that usually keeps immune responses in check, making it easier for the body to attack cancer cells.

Phase 3 Trials

Trials With No Placebo

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.